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Abstract
Background: An important objective on diagnosis of patients with Langerhans cell histiocytosis (LCH) is to
determine the extent of disease. However, whether systematic extrathoracic investigation is needed in adult
patients with clinically isolated pulmonary LCH (PLCH) has not been evaluated.
Methods: In this prospective, multicentre study, 54 consecutive patients with newly diagnosed clinically isolated
PLCH were systematically evaluated at inclusion by bone imaging and blood laboratory testing to search for
subclinical extrapulmonary LCH involvement. The patients were followed over a 2-year period. At each visit, they
were asked about the presence of extrapulmonary manifestations of LCH.
Results: In the absence of bone symptoms, the skeletal X-ray survey results were normal for all but two
patients who had a localised bone lesion consistent with possible LCH involvement, that remained
unchanged over 2 years of follow-up. Whole-body bone scintigraphy did not add information to the plain
radiography findings for the detection of asymptomatic bone involvement in isolated PLCH. Conversely, it
showed nonspecific focal bone uptake in 18 % of the patients, mainly corresponding to post-traumatic or
degenerative abnormalities unrelated to LCH. Mild leucocytosis due to neutrophilia was observed in 22 % of
the patients and was not related to their smoking habits. Three patients had mild isolated lymphocytosis
without haematological disease, whereas two patients had mild lymphopaenia. A mild inflammatory biological
syndrome was observed in a minority of patients without infection or constitutional symptoms and was not
associated with progressive disease. A substantial proportion (24.5 %) of the patients had abnormal biological
liver test results, including elevated liver enzymes and/or cholestasis, which were not linked to LCH
involvement in this cohort.
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Conclusions: Obtaining a thorough history and performing comprehensive physical examination are essential for
staging patients diagnosed with PLCH. In the absence of symptoms or signs suggestive of extrapulmonary LCH
involvement, the systematic performing of recommended bone imaging does not appear informative. Although
the observed blood laboratory abnormalities were not specifically related to LCH, performing these tests in the
diagnostic workup for PLCH is useful because some of these alterations may impact patient management.
Trial registration: ClinicalTrials.gov: No. NCT01225601; URL: www.clinicaltrials.gov
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Background
Adult pulmonary Langerhans cell histiocytosis (LCH) is
a rare disorder of unknown aetiology that occurs pre-
dominantly in young smokers, with an incidence peak at
20–40 years of age [1, 2]. Although pulmonary involve-
ment in LCH may be part of a multisystem disease [3–
5], pulmonary LCH (PLCH) occurs frequently as a
single-system disease in adults [1, 2].
An important objective upon LCH diagnosis is to de-
termine the extent of disease [6]. Therefore, obtaining a
thorough history and performing a comprehensive clin-
ical evaluation, several laboratory tests, and bone im-
aging are recommended for all adult LCH patients,
regardless of the primary manifestation of the disease
[6]. However, whether a similar approach is needed for
adult patients with clinically isolated PLCH has not yet
been evaluated. To address this issue, we examined data
from our prospective multicentre study that evaluated
the natural history of recently diagnosed PLCH [7], in
which the patients systematically underwent bone im-
aging and blood testing at the time of inclusion.
Methods
Study design
This is an ancillary study derived from a recently re-
ported prospective, multicentre study conducted by the
French National Reference Centre for Langerhans Cell
Histiocytosis, in which the natural history of adult PLCH
patients was evaluated [7]. The study protocol was ap-
proved by the appropriate ethics committee in February
2006 (N°2006/03, CCPPRB IDF4, Paris). Consecutive pa-
tients who were 18 years of age or older and were re-
ferred for PLCH to the participating centres were
considered eligible, provided they had not received treat-
ment for their disease. The main exclusion criterion was
the presence of extrapulmonary involvement of LCH,
except for localised bone lesions. All patients provided
written informed consent.
At the time of inclusion in the study, a comprehensive
clinical evaluation, including a thorough history and a
search for the presence of respiratory and constitutional
symptoms (e.g., fever, night sweats, and body weight
changes) and extrapulmonary manifestations of LCH
were performed. In addition, bone imaging and blood la-
boratory testing were systematically conducted. Because
head MRI is not systematically recommended [6], it was
not included in the imaging workup.
Study subjects
Among the 58 patients included in our initial study [7],
four were secondarily excluded because of symptomatic
LCH bone involvement detected upon PLCH diagnosis
(n = 3) or at the time of inclusion (n = 1). They com-
plained of bone pain and had typical LCH osteolytic le-
sions. In two of these patients, bone involvement was
the first sign of LCH and was histologically confirmed.
The characteristics of the remaining 54 patients with
clinically isolated PLCH at the time of inclusion are
shown in Table 1. No patient had symptoms or signs
suggestive of extrapulmonary LCH. The diagnosis of
PLCH either was histologically confirmed by a surgical
lung biopsy (n = 19) or was based on the combination of
an appropriate clinical setting, a typical lung high-
resolution computed tomography (HRCT), a marked
predominance of alveolar macrophages in bronchoalveo-
lar lavage, and exclusion of alternative diagnoses (n = 35)
[7].
Bone imaging
Skeletal X-ray survey was performed, consisting of an-
teroposterior and lateral views of the skull and spine, as
well as anteroposterior views of the ribs, pelvis, and
upper and lower limbs. A dental panoramic radiograph
was also obtained.
All patients had a chest CT at the time of inclusion as
part of pulmonary evaluation [7], and eventual LCH in-
volvement of the thoracic bones was systematically
assessed by analysing CT images with bone window
settings (width: 2000, level: 300).
Whole-body bone scintigraphy was also systematically
performed at inclusion. The patients were injected intra-
venously with technetium (Tc)-99 m-radiolabelled
bisphosphonates. At least 2 h after tracer injection, total
body imaging (planar anterior and posterior views) was
performed with a dedicated dual-head gamma camera.
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Complementary static images were captured only if
deemed necessary.
Blood laboratory tests
At inclusion, a complete blood count (haemoglobin,
white blood cell and differential counts and a platelet
count) and blood chemistry analysis (total protein,
electrolyte, creatinine, bilirubin, alanine aminotransfer-
ase (ALT), aspartic aminotransferase (AST), alkaline
phosphatase (AP), gammaglutamyl transpeptidase
(γGT), C-reactive protein (CRP), and fibrinogen
levels) were performed. In our experience, all adult
patients with LCH pituitary involvement and diabetes
insipidus complain of polyuria/polydipsia. Therefore,
morning urinary osmolarity was not included in the
biological workup.
Data collection
The patients were managed as outpatients at each
study centre. Study visits occurred at baseline and at
3, 6, 12, 18, and 24 months. A standardised case re-
port form was completed at each investigation centre.
The data were monitored by independent clinical
research assistants. At each visit, the presence of re-
spiratory, constitutional and extrapulmonary manifes-
tations of LCH was recorded. Bone radiographs and
99m-Tc bone scans were interpreted by expert radiolo-
gists and nuclear physicians, respectively, at each par-
ticipating centre. Lung CT scans were centrally
analysed by a radiologist (C de M). The blood labora-
tory test results were interpreted according to the
normal reference values. In cases of abnormal find-
ings, additional investigations were carried out as
needed to establish a cause of the abnormality and to
manage the patient.
Statistical analysis
Descriptive statistics are presented as median (interquar-
tile range [IQR]) values. Comparisons between the
groups at inclusion, as defined by the blood leucocyte
count or biological inflammation, were conducted using
Fisher’s exact test or the nonparametric Wilcoxon test
for qualitative and quantitative variables, respectively.
All statistical analyses were performed using SAS 9.3
(SAS Inc., Cary, NC, USA) and R 3.0.2 (http://www.R-




Fifty-one (94.4 %) patients received skeletal X-ray survey
at inclusion. One patient had a lytic lesion of the left
femoral diaphysis, confirmed by bone MRI, which was
consistent with possible LCH involvement. During the
24 months of follow-up in the study, this patient did not
present bone symptoms, the femoral lesion remained
stable, and no other bone localisation appeared. Another
patient had fracture sequelae of the 8th right rib on plain
radiography that was also visible on chest CT. This le-
sion remained unchanged at 2 years of follow-up. Be-
cause these two patients had no symptoms, the eventual
LCH bone involvement was not confirmed by a bone bi-
opsy. The 49 remaining patients had normal skeletal X-
ray survey findings. With the exception of the patient
with fracture sequelae of the 8th right rib, no patient
had a thoracic bone lesion on chest CT.
Of the 47 (87 %) patients who received dental pano-
ramic radiography, 44 had normal findings. Three pa-
tients exhibited extensive loss of the teeth, without
mandible/maxillary alveolar or basal bone lytic lesions.
These patients were referred to the maxillofacial surgery
clinic and none complained of previous or current den-
tal or oral mucosa symptoms suggestive of LCH. It was
concluded that the previous extensive tooth extractions
were related to poor oral hygiene and periodontitis
favoured by their heavy smoking habits.
All 54 patients underwent whole-body bone scintig-
raphy at inclusion. The bone scan was normal in 43
(80 %) patients, including the patient with the lytic le-
sion of the left femoral diaphysis. The patient with
fracture sequelae of the 8th right rib showed mild focal
99m-Tc uptake. For the 10 (18 %) remaining patients,
bone scan showed mild focal 99m-Tc uptake at different
skeletal sites, whereas skeletal X-rays showed no
histiocytosis-related lesions in the corresponding areas
(Table 2).
Blood laboratory test findings
All patients had normal blood total protein, electrolyte
and creatinine levels. Twelve (22 %) patients had an
Table 1 Baseline characteristics of the patients at inclusion in
the study
Characteristic N = 54
Age, yrs, median, [IQR] 35.5 [27–42]




16.5 [9–25]38 (70 %)16
(30 %)
Clinical features, n (%)




History of pneumothorax 11 (20 %)
Constitutional symptoms* 6 (11 %)
Abbreviation definitions: IQR interquartile range
*Constitutional symptoms were associated with respiratory symptoms in
four patients
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increased white blood cell count (median = 12.75 G/L,
IQR 12-13.3 G/L; normal range 4–10 G/L). Among
these patients, 11 had neutrophilia (median = 8.9 G/L,
IQR 8.5-9.5 G/L; normal range 1.7–8.0 G/L), and two
had an associated mild increase in the lymphocyte count
(5.9 G/L, and 4.8 G/L, respectively; normal range 1.5–
4.0 G/L). Another patient had mild isolated lymphocyto-
sis (5.3 G/L). No association was observed with smoking
status (current vs. ex-smoker) at inclusion (p = 0.73),
daily cigarette consumption (p = 0.98) or cumulative to-
bacco smoking, expressed as pack-year (p = 0.37). Add-
itionally, two patients presented mild lymphopaenia (1.3
and 1.1 G/L, respectively) with a normal total blood
count. These two patients had no other cause of
lymphopaenia.
A mild inflammatory biological syndrome was ob-
served in 5 patients (CRP = 29 to 49 mg/L, n = 4; normal
value < 10 mg/L; fibrinogen = 4.6 to 7.3 g/L, n = 3; nor-
mal range 2–4 g/L). None of these patients had constitu-
tional symptoms or progressive disease. No association
was observed with smoking status (p = 0.31).
Thirteen of the 53 patients (24.5 %) had abnormal bio-
logical liver test results, including elevated liver enzymes
and/or cholestasis. All these patients were referred to
the hepatology department at their investigating centre.
Additional tests, including hepatitis virus serology and
auto-immune antibody testing, hepatic imaging (ultra-
sound and MR cholangiography), and, in one case, liver
biopsy, were performed. The biological liver abnormal-
ities were not related to LCH involvement in any of the
cases. The diagnoses retained for the biological liver
abnormalities in these patients are shown in Table 3.
Discussion
This is the first study to evaluate the utility of systematic
extrathoracic examination in adult patients with clinic-
ally isolated PLCH. We report the following findings: 1)
in the absence of bone symptoms, skeletal X-ray survey
was virtually consistently normal; 2) bone scan did not
add information to plain radiography and showed non-
specific focal 99m-Tc uptake corresponding to post-
traumatic or degenerative lesions in a significant minor-
ity of the patients; and 3) routine biological blood tests
showed various abnormalities that were not specifically
related to LCH.
Bone involvement is known to occur in adult PLCH
[1, 2]. Several retrospective studies have demonstrated
that bone involvement occurs in approximately 10 % of
adult PLCH patients [8–12]; however, these studies did
not specify whether the patients had bone symptoms. In
a former large retrospective series, Friedman et al. “inci-
dentally” detected bone involvement in only 4 out of 100
PLCH patients [13]. Among a multicentre prospective
cohort of 77 PLCH patients, Schönfeld et al. identified
eight (10 %) with clinical signs of bone involvement at
the time of diagnosis [14]. In a recent single-centre
series of 40 PLCH adult patients, two (5 %) had symp-
tomatic bone involvement at diagnosis, and seven (18 %)
had radiographic LCH bone involvement [15]. However,
it is unclear whether all of the patients underwent skel-
etal radiography at diagnosis and if the bone radiographs
were obtained because of the occurrence of bone symp-
toms during follow-up.
Because LCH may involve the jaw [5, 16], dental pano-
ramic radiography was included as part of bone imaging
at inclusion in our study, showing normal results for all
of the patients except for three who presented extensive
tooth loss. None of these patients exhibited mandible/
maxillary lytic lesions of the alveolar or basal bones.
These patients did not complain of previous dental or
oral signs suggestive of LCH. They had previous exten-
sive dental extractions related to poor oral hygiene and
periodontitis favoured by their heavy smoking habits.
The contribution of bone scanning to the identifica-
tion of LCH bone lesions has been controversial for a
long time, and appears to be less sensitive than plan
radiography [17–19]. Our results clearly demonstrate
that bone scanning does not provide any added contri-
bution to skeletal radiography for detecting asymptom-
atic bone involvement in PLCH. Whole-body bone
scintigraphy did not identify the femur lytic lesion ob-
served on skeletal X-ray. Conversely, bone scan showed
nonspecific focal 99m-Tc bone uptake in a substantial
proportion of the patients, mainly corresponding with
post-traumatic or degenerative abnormalities unrelated
to LCH. None of these patients developed secondary
LCH bone involvement.
18-FDGPET-CT was shown to be more sensitive that
skeletal X-ray survey to detect bone LCH, particularly
some localisations such as rib and pelvic lesions [20].
Furthermore, FDG uptake was correlated with the
Table 2 99m-Tc bone scintigraphy for the 10 PLCH patients with
normal skeletal X-ray survey at inclusion
Patient 99m-Tc bone scintigraphy findings
1 Focal uptake of proximal right humerus (post-traumatic)
2 Uptake of lateral part of L4-L5
3 Mild uptake of 4th left rib
4 Moderate uptake of 9th right rib
5 Mild uptake of proximal right tibia
6 Mild uptake of lateral part of left C7
7 Uptake of right C7
8 Uptake of right lateral part of L1
9 Uptake of right lateral part of D11
10 Focal uptake of left patella and upper part of right orbit
Abbreviation definitions: L lumbar vertebra, C cervical vertebra, D
dorsal vertebra
Tazi et al. Orphanet Journal of Rare Diseases  (2016) 11:11 Page 4 of 6
activity of bone disease and was useful for following
the disease course and evaluating response to treat-
ment [20]. However, whether 18-FDGPET-CT should be
systematically performed as part of diagnostic workup
for patients with clinically isolated PLCH (i.e. with no
bone symptoms) is questionable and remains to be
evaluated. The increased radiation exposure in these
young patients is also a concern.
Whereas routine blood electrolyte and renal func-
tion testing showed consistently normal results in our
cohort, a slightly increased blood leucocyte count was
observed in 22 % of the patients. This leucocytosis
was due to neutrophilia in all but one of the patients.
Although smoking is known to induce leucocytosis
[21], we did not find any statistical association
between the patients’ blood leucocytosis and their
smoking habits. Three patients (5 %) had mild lym-
phocytosis without haematological disease. Conversely,
two patients had mild lymphopaenia, which is
unusual in LCH patients in the absence of immuno-
suppressive therapy. No other causes of lymphopenia,
such as HIV infection, were found.
A mild biological inflammatory syndrome may have
been present in a small proportion of the patients with
clinically isolated PLCH, in the absence of any constitu-
tional symptoms or infection. This inflammatory syn-
drome was not associated with progression of the
disease.
The liver biological blood tests revealed the most
salient blood abnormalities in this study. Different
patterns of biological liver abnormalities were ob-
served, i.e., elevated liver enzymes and/or cholestasis.
In our cohort, these abnormalities were not related to
LCH liver involvement. The main aetiology of the
biological liver abnormalities was excessive alcohol
consumption. This possibly reflects the consumption
level of the general French population or a particular
addictive tendency of PLCH patients towards alcohol,
in the same manner as that to tobacco [1, 2].
Although the laboratory blood abnormalities observed
were not specifically related to LCH, in our opinion,
these tests merit systematic administration at the time of
PLCH diagnosis for several reasons. First, haemato-
logical disorders (leukaemia or lymphoma) may be asso-
ciated with LCH, including adult PLCH [11, 22, 23], and
they may thus be screened using these blood tests. Sec-
ond, although it was not the case in our cohort, liver
LCH involvement in adult PLCH patients has been re-
ported [24–26]. Finally, the presence of lymphopaenia
and biological liver alterations is important to consider
in patients who will eventually need treatment for their
disease. In particular, cladribine, a promising treatment
for progressive PLCH [27, 28], is known to induce deep
and prolonged lymphopaenia and hepatic side effects
[29].
Conclusions
Our results highlight the importance of obtaining a
thorough history and performing comprehensive
physical examination to search for extrapulmonary in-
volvement in adult PLCH patients. In the absence of
symptoms or signs suggestive of extrapulmonary LCH
involvement, the systematic performing of recom-
mended bone imaging does not appear informative.
The prospective and multicentre design of our study
enhances the external validity of this finding. Con-
versely, blood cell count and liver biological assess-
ments should be performed in diagnostic workup
because they can reveal abnormalities that have po-
tential impacts on patient management. Additional
studies are needed to determine if these biological
tests should be systematically repeated during the
follow-up of patients with normal initial assessment.
Abbreviations
ALT: alanine aminotransferase; AP: alkaline phosphatase; AST: aspartic
aminotransferase; CRP: C-reactive protein; CT: computed tomography;
IQR: interquartile range; LCH: langerhans cell histiocytosis; MRI: magnetic
resonance imaging; SD: standard deviation; γGT: gammaglutamyl
transpeptidase.
Competing interests
A. Tazi has no conflicts of interest to declare.
C. de Margerie-Mellon has no conflicts of interest to declare.
L. Vercellino has no conflicts of interest to declare.
J.M. Naccache has no conflicts of interest to declare.
S. Fry has no conflicts of interest to declare.
Table 3 Retained diagnoses for the 13 PLCH patients with
abnormal liver biological test results at inclusion
Patient AST ALT AP γGT Diagnosis
1 N N N 2.3 N Alcohol consumption
2 N N 2 N 4 N Alcohol consumption (negative
results for hepatitis virus serology,
auto-antibodies and MR
cholangiography)
3 N N 1.3 N 1.8 N Drug induced
4 N N N 2.5 N Liver steatosis
5 1.3 N 1.2 N N 4.9 N Alcohol consumption
6 N N N 6 N Alcohol consumption
7 1.9 N 2 N N 6 N Alcohol consumption
8 N 1.2 N N 2 N Alcohol consumption
9 N 1.5 N N 2 N Liver steatosis
10 N 2 N 1.3 N 2 N No diagnosis, lost to follow-up
11 N N N 2 N Liver steatosis
12 N N N 3.6 N Alcohol acute pancreatitis
13 N N N 1.7 N Alcohol consumption
Abbreviation definitions: AST aspartic aminotransferase, ALT alanine
aminotransferase, AP alkaline phosphatase, γGT gammaglutamyl
transpeptidase, N normal value, MR magnetic resonance
Tazi et al. Orphanet Journal of Rare Diseases  (2016) 11:11 Page 5 of 6
S. Dominique has no conflicts of interest to declare.
S. Jouneau has no conflicts of interest to declare.
G. Lorillon has no conflicts of interest to declare.
E. Bugnet has no conflicts of interest to declare.
R. Chiron has no conflicts of interest to declare.
B. Wallaert has no conflicts of interest to declare.
D. Valeyre has no conflicts of interest to declare.
S. Chevret has no conflicts of interest to declare.
Authors’ contributions
AT and SC had full access to the study data and take responsibility for the
content of the manuscript, including the data and analysis. AT and SC
contributed to the conception and design of the study, analysis and
interpretation of the data, drafting of the article, revising of the paper and
final approval of the manuscript. C de M, LV, JMN, SF, SD, SJ, GL, EB, RC, BW
and DV contributed to acquisition of the data, revising of the manuscript
and the final approval. All authors have agreed to be accountable for all
aspects of the work to ensure that questions related to the accuracy or
integrity of any part of the work are appropriately investigated and resolved.
Acknowledgements
The authors are grateful to M. Mao (Assistance Publique-Hôpitaux de Paris;
Service de Pneumologie, Hôpital Saint-Louis, Paris, France) for her technical
assistance.
Author details
1Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Centre National
de Référence de l’histiocytose Langerhansienne, Service de Pneumologie, 1
Avenue Claude Vellefaux, 75475 cedex 10 Paris, France. 2Université Paris
Diderot, Sorbonne Paris Cité, U1153 CRESS, Biostatistics and Clinical
Epidemiology research team, Paris, France. 3Assistance Publique-Hôpitaux de
Paris, Service de Radiologie, Hôpital Saint-Louis, Paris, France. 4Assistance
Publique-Hôpitaux de Paris, Service de Médecine Nucléaire, Hôpital
Saint-Louis, Paris, France. 5Assistance Publique-Hôpitaux de Paris, Service de
Pneumologie, Hôpital Avicenne, Bobigny, France. 6Service de Pneumologie
et Immuno-allergologie, Centre de compétence des maladies pulmonaires
rares, Hôpital Calmette, Lille, France. 7Département de Pneumologie, Hôpital
Charles Nicolle, Rouen, France. 8IRSET UMR 1085, Université de Rennes 1;
Service de Pneumologie, Hôpital Pontchaillou, Rennes, France. 9Département
de Pneumologie, Hôpital Arnaud de Villeneuve, Montpellier, France.
10Université Lille 2, Lille, France. 11Université Paris 13, Sorbonne Paris Cité;
Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital
Avicenne, Bobigny, France. 12Assistance Publique-Hôpitaux de Paris; Hôpital
Saint-Louis, Service de Biostatistique et Information Médicale, Paris, France.
Received: 7 November 2015 Accepted: 13 January 2016
References
1. Suri H, Yi ES, Nowakowski GS, Vassallo R. Pulmonary langerhans cell
histiocytosis. Orphanet J Rare Dis. 2012;7(1):16.
2. Tazi A. Adult pulmonary Langerhans’ cell histiocytosis. Eur Respir J. 2006;
27(6):1272–85.
3. Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, Grois N, et al.
Langerhans cell histiocytosis in adults. Report from the International
Registry of the Histiocyte Society. Eur J Cancer. 2003;39(16):2341–8.
4. Howarth DM, Gilchrist GS, Mullan BP, Wiseman GA, Edmonson JH,
Schomberg PJ. Langerhans cell histiocytosis: diagnosis, natural history,
management, and outcome. Cancer. 1999;85(10):2278–90.
5. Stockschlaeder M, Sucker C. Adult Langerhans cell histiocytosis. Eur J
Haematol. 2006;76(5):363–8.
6. Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C, Fichter J, et al.
Management of adult patients with Langerhans cell histiocytosis:
recommendations from an expert panel on behalf of Euro-Histio-Net.
Orphanet J Rare Dis. 2013;8:72.
7. Tazi A, de Margerie C, Naccache JM, Fry S, Dominique S, Jouneau S, et al.
The natural history of adult pulmonary Langerhans cell histiocytosis: a
prospective multicentre study. Orphanet J Rare Dis. 2015;10(1):30.
8. Crausman RS, Jennings CA, Tuder RM, Ackerson LM, Irvin CG, King Jr TE.
Pulmonary histiocytosis X: pulmonary function and exercise
pathophysiology. Am J Respir Crit Care Med. 1996;153(1):426–35.
9. Schonfeld N, Frank W, Wenig S, Uhrmeister P, Allica E, Preussler H, et al.
Clinical and radiologic features, lung function and therapeutic results in
pulmonary histiocytosis X. Respiration. 1993;60(1):38–44.
10. Travis WD, Borok Z, Roum JH, Zhang J, Feuerstein I, Ferrans VJ, et al.
Pulmonary Langerhans cell granulomatosis (histiocytosis X). A
clinicopathologic study of 48 cases. Am J Surg Pathol. 1993;17(10):971–86.
11. Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes
of pulmonary Langerhans’-cell histiocytosis in adults. N Engl J Med. 2002;
346(7):484–90.
12. Watanabe R, Tatsumi K, Hashimoto S, Tamakoshi A, Kuriyama T. Clinico-
epidemiological features of pulmonary histiocytosis X. Intern Med. 2001;
40(10):998–1003.
13. Friedman PJ, Liebow AA, Sokoloff J. Eosinophilic granuloma of lung. Clinical
aspects of primary histiocytosis in the adult. Medicine (Baltimore). 1981;
60(6):385–96.
14. Schonfeld N, Dirks K, Costabel U, Loddenkemper R. A prospective clinical
multicentre study on adult pulmonary Langerhans’ cell histiocytosis.
Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):132–8.
15. Elia D, Torre O, Cassandro R, Caminati A, Harari S. Pulmonary Langerhans
cell histiocytosis: A comprehensive analysis of 40 patients and literature
review. Eur J Intern Med. 2015;26(5):351–6.
16. Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F.
Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol. 1997;28(1):9–14.
17. Howarth DM, Mullan BP, Wiseman GA, Wenger DE, Forstrom LA, Dunn WL.
Bone scintigraphy evaluated in diagnosing and staging Langerhans’ cell
histiocytosis and related disorders. J Nucl Med. 1996;37(9):1456–60.
18. Meyer JS, Harty MP, Mahboubi S, Heyman S, Zimmerman RA, Womer RB,
et al. Langerhans cell histiocytosis: presentation and evolution of radiologic
findings with clinical correlation. Radiographics. 1995;15(5):1135–46.
19. Schaub T, Ash JM, Gilday DL. Radionuclide imaging in histiocytosis X.
Pediatr Radiol. 1987;17(5):397–404.
20. Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to
conventional radiography and bone scans in management of Langerhans
cell histiocytosis. Pediatr Blood Cancer. 2009;52(1):97–101.
21. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF.
Systemic effects of smoking. Chest. 2007;131(5):1557–66.
22. Egeler RM, Neglia JP, Arico M, Favara BE, Heitger A, Nesbit ME, et al. The
relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and
other solid tumors. The LCH-Malignancy Study Group of the Histiocyte
Society. Hematol Oncol Clin North Am. 1998;12(2):369–78.
23. Feuillet S, Louis L, Bergeron A, Berezne A, Dubreuil ML, Polivka M, et al.
Pulmonary Langerhans cell histiocytosis associated with Hodgkin’s
lymphoma. Eur Respir Rev. 2010;19(115):86–8.
24. Abdallah M, Genereau T, Donadieu J, Emile JF, Chazouilleres O, Gaujoux-
Viala C, et al. Langerhans’ cell histiocytosis of the liver in adults. Clin Res
Hepatol Gastroenterol. 2011;35(6-7):475–81.
25. Araujo B, Costa F, Lopes J, Castro R. Adult langerhans cell histiocytosis with
hepatic and pulmonary involvement. Case Rep Radiol. 2015;2015:536328.
26. Konno S, Hizawa N, Betsuyaku T, Yasuo M, Yamamoto H, Koizumi T, et al.
Adult Langerhans cell histiocytosis with independently relapsing lung and
liver lesions that was successfully treated with etoposide. Intern Med. 2007;
46(15):1231–5.
27. Grobost V, Khouatra C, Lazor R, Cordier JF, Cottin V. Effectiveness of
cladribine therapy in patients with pulmonary Langerhans cell histiocytosis.
Orphanet J Rare Dis. 2014;9(1):191.
28. Lorillon G, Bergeron A, Detourmignies L, Jouneau S, Wallaert B, Frija J, et al.
Cladribine is effective against cystic pulmonary Langerhans cell histiocytosis.
Am J Respir Crit Care Med. 2012;186(9):930–2.
29. Robak T, Korycka A, Robak E. Older and new formulations of cladribine.
Pharmacology and clinical efficacy in hematological malignancies. Recent
Pat Anticancer Drug Discov. 2006;1(1):23–38.
Tazi et al. Orphanet Journal of Rare Diseases  (2016) 11:11 Page 6 of 6
